Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Mild cognitive impairment

Topic: Risk, prevention and care in population studies

There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD-I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre-mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus.

Key findings

Why it matters

This paper presents a conceptual framework and research criteria for studying subjective cognitive decline in preclinical Alzheimer's disease. It is a framework paper and does not directly address treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 60/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 5 of 6; Still being cited 4 of 4; Senior author's track record left out, no data; Institution's track record 3 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 58 of the 96 points it could be judged on, which is 60 of 100. Total 60 of 100.58 of the 96 points we could judge = 60 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 58 of the 96 points we could judge it on, which is 60 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2014 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 3,017 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 215.5 citations a year over 14 year(s) since 2014
Impact for its field and year 6 / 6 Cited 68.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 5 / 6 Cited by 121 other studies in this library
Still being cited 4 / 4 Cited 1,067 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 31 institution(s) in 7 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 24798886)
Free to read 2 / 2 Free to read
Points 58 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 96 points we could judge it on is 60 out of 100.
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Jessen, F., Amariglio, R. E., van Boxtel, M. P., Breteler, M. M., Ceccaldi, M., Chételat, G., et al. (2014). A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2014.01.001

Vancouver

Jessen F, Amariglio RE, van Boxtel MP, Breteler MM, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer s & Dementia. 2014. doi:10.1016/j.jalz.2014.01.001. PMID: 24798886.

BibTeX

@article{jessen2014-24798886,
  author  = {Jessen, Frank and Amariglio, Rebecca England and van Boxtel, Martin P.J. and Breteler, Monique M.B. and Ceccaldi, Mathieu and Chételat, Gaël and Dubois, Bruno and Dufouil, Carole and others},
  title   = {{A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease}},
  journal = {Alzheimer s \& Dementia},
  year    = {2014},
  doi     = {10.1016/j.jalz.2014.01.001},
  pmid    = {24798886},
  url     = {https://doi.org/10.1016/j.jalz.2014.01.001}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

121 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →